Article
Rheumatology
Cindy L. J. Weinstein, Alan G. Meehan, Jianxin Lin, Steven D. Briscoe, Marinella Govoni
Summary: This study analyzed the long-term persistence of golimumab treatment in patients with rheumatic diseases over a period of five years. The findings showed that golimumab had consistently high retention rates when used as first-line therapy and lower rates when used as second-line therapy, with patients on second-line therapy having a longer disease duration.
CLINICAL RHEUMATOLOGY
(2023)
Article
Dermatology
Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C. Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip J. Mease, Mark Lebwohl
Summary: This study reports the long-term safety of Secukinumab in a large dataset, including patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. The results show that Secukinumab has a favorable safety profile for up to 5 years of treatment in these indications, and no new safety signals were identified.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Rheumatology
M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh
Summary: The safety profile of IV golimumab in treating rheumatologic diseases was similar to that of other TNFi, and the concomitant use of methotrexate or corticosteroids was associated with an increase in certain adverse events.
ARTHRITIS RESEARCH & THERAPY
(2022)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Xabier Michelena, Clementina Lopez-Medina, Alba Erra, Xavier Juanola, Pilar Font-Ugalde, Eduardo Collantes, Helena Marzo-Ortega
Summary: This study compared the clinical and radiographical characteristics of axial psoriatic arthritis (PsA) with ankylosing spondylitis (AS) with psoriasis. It found that axial PsA is predominantly HLA-B27 negative and has different manifestations compared to AS with psoriasis. There is great heterogeneity in the definition of axial PsA from a clinical and imaging perspective.
Article
Rheumatology
Timothy S. H. Kwok, Mitchell Sutton, Daniel Pereira, Richard J. Cook, Vinod Chandran, Nigil Haroon, Robert D. Inman, Dafna D. Gladman
Summary: Isolated axial PsA and AS with psoriasis are relatively uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may predict the development of peripheral disease. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Clementina Lopez-Medina, Anna Molto, Joachim Sieper, Tuncay Duruoz, Uta Kiltz, Bassel Elzorkany, Najia Hajjaj-Hassouni, Ruben Burgos-Vargas, Jose Maldonado-Cocco, Nelly Ziade, Meghna Gavali, Victoria Navarro-Compan, Shue-Fen Luo, Sara Monti, Kim Tae-Jong, Mitsumasa Kishimoto, F. M. Pimentel-Santos, Jieruo Gu, Ruxandra Schiotis, Floris A. van Gaalen, Pal Geher, Marina Magrey, Sebastian E. Ibanez Vodnizza, Wilson Bautista-Molano, Walter Maksymowych, Pedro M. Machado, Robert Landew, Desiree van der Heijde, Maxime Dougados
Summary: This study included 4465 patients with SpA from 24 countries around the world, showing quantitative differences in peripheral manifestations among different subtypes but no significant qualitative differences. It was found that a high proportion of patients with SpA had both axial and peripheral manifestations coinciding.
Article
Rheumatology
Adrian Ciurea, Andrea Gotschi, Seraphina Kissling, Alexander Bernatschek, Kristina Burki, Pascale Exer, Michael J. Nissen, Burkhard Moller, Almut Scherer, Raphael Micheroli
Summary: This study compared the characteristics of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and found differences in demographic and clinical features between the two groups, but a similar disease burden.
Review
Rheumatology
Ana De Vicente Delmas, Lara Sanchez-Bilbao, Vanesa Calvo-Rio, David Martinez-Lopez, Alba Herrero-Morant, Eva Galindez-Agirregoikoa, Inigo Gonzalez-Mazon, Nuria Barroso-Garcia, Natalia Palmou-Fontana, Miguel A. Gonzalez-Gay, Jose L. Hernandez, Ricardo Blanco
Summary: This study aimed to assess the frequency and clinical features of uveitis in psoriatic arthritis (PsA) patients, as well as its association with disease activity, functional disability, and biological treatment. The prevalence of uveitis in PsA patients was about 5%, and it was associated with a worse quality of life and greater functional disability. The incidence rate of uveitis varied depending on the type of biological treatment used.
Article
Rheumatology
Christina Charles-Schoeman, Ernest Choy, Iain B. McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K. Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R. Curtis
Summary: This study provides an integrated analysis of major adverse cardiovascular events (MACEs) and venous thromboembolism (VTE) events in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients treated with upadacitinib. The results show that the rates of MACEs and VTE events with upadacitinib are similar to those reported for conventional synthetic and biologic disease-modifying drugs, and comparable to adalimumab and methotrexate.
Article
Rheumatology
Xenofon Baraliakos, Effie Pournara, Laure Gossec, Philip J. Mease, Roisin White, Eamonn O'Brien, Barbara Schulz, Helena Marzo-Ortega, Laura C. Coates
Summary: This study investigated patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis with axial manifestations. Nail dystrophy was identified as a predictor of response to secukinumab in these patients.
Article
Medicine, General & Internal
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Desiree van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In-Ho Song
Summary: Upadacitinib demonstrates significant efficacy and safety in patients with non-radiographic axial spondyloarthritis.
Article
Rheumatology
Lin Wang, Xiaofang Ping, Wei Chen, Weibin Xing
Summary: The study confirmed the effectiveness of JAK inhibitors in improving the condition of both PsA and AS patients, as well as in alleviating psoriasis-related dermal lesions. Higher doses of tofacitinib yielded better treatment responses, though with increased safety concerns.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Anton Jonatan Landgren, Mats Dehlin, Lennart Jacobsson, Ulrika Bergsten, Eva Klingberg
Summary: The study aimed to compare traditional cardiovascular risk factors among patients with different rheumatic diseases, and found that hypertension was the most common comorbidity, with patients with gout having the highest prevalence of traditional CVRFs. Significant differences in occurrence of CVRFs by sex were also observed among patients with PsA, RA and AS.
Article
Rheumatology
Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith
Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
